公开(公告)号：JP2012121921A

公开(公告)日：2012-06-28

申请号：JP2012054340

申请日：2012-03-12

Applicant: Ucb Pharma Sa ,  ユセベ ファルマ ソシエテ アノニム

Inventor： KENDA BENOIT ,  QUESNEL YANNICK ,  ATES ALI ,  MICHEL PHILIPPE ,  TURET LAURENT ,  MERCIER JOEL

IPC: C07D401/06 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/429 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61P9/00 ,  A61P9/10 ,  A61P11/06 ,  A61P25/02 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/36 ,  A61P27/16 ,  A61P37/08 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07D513/04

CPC classification number: C07D513/04 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04

Abstract: PROBLEM TO BE SOLVED: To provide a new 2-oxo-1-pyrrolidine derivative, a process for preparing the same, a pharmaceutical composition containing the same, and use thereof as a pharmaceutical.SOLUTION: There are provided a compound having formula, a geometrical isomer thereof, an enantiomer, a diastereoisomer and a mixture, or a pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition containing the same, and use thereof as a pharmaceutical.

Abstract translation: 待解决的问题：为了提供新的2-氧代-1-吡咯烷衍生物，其制备方法，含有它们的药物组合物及其作为药物的用途。 提供了具有式的化合物，其几何异构体，对映异构体，非对映异构体和其混合物或其药学上可接受的盐，其制备方法，含有该化合物的药物组合物和使用的药物组合物 作为药物。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：WO2008132142A3

公开(公告)日：2009-01-15

申请号：PCT/EP2008055022

申请日：2008-04-24

Applicant: UCB PHARMA SA ,  KENDA BENOIT ,  TURET LAURENT ,  QUESNEL YANNICK ,  MICHEL PHILIPPE ,  ATES ALI

Inventor： KENDA BENOIT ,  TURET LAURENT ,  QUESNEL YANNICK ,  MICHEL PHILIPPE ,  ATES ALI

IPC: A61K31/4015 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/417 ,  A61K31/421 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61K31/45 ,  A61K31/4704 ,  A61K31/472 ,  A61K31/55 ,  C07D207/38 ,  C07D215/22 ,  C07D233/32

CPC classification number: C07D233/32 ,  A61K31/4015 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/417 ,  A61K31/421 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61K31/45 ,  A61K31/4704 ,  A61K31/472 ,  A61K31/55 ,  C07D215/227 ,  C07D217/24 ,  C07D263/20 ,  C07D263/22 ,  C07D263/38 ,  C07D277/14 ,  C07D277/34 ,  C07D277/68 ,  C07D401/06 ,  C07D403/06 ,  C07D417/06 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00

Abstract: The present invention relates to compounds having the formula (I), its geometrical isomers, enantiomers, diastereomers and mixtures, or a pharmaceutically acceptable salt thereof, wherein Y is O, S or NR8; R1 is hydrogen or C1-6 alky!; R2 is hydrogen; R3 is -CONR5R6, -COR7, an imidazolyl, an imidazopyridinyl, an imidazopyridazinyl or a 1 H-indol-1-yl; R5, R6 are the same or different and are independently selected from hydrogen and C1-6 alkyl; R7 is a C1-6 alkyl; R8 is CN or C1-6 alkylsulfonyl; A is a monocyclic or bicyclic heterocyclic moiety selected from the group consisting of imidazolidin-1-yl, 1,3-oxazoIidin-3-yl, 2,5dihydro-1H-pyrrol-1-yl, 1,3-thiazol-3(2H)-yl, 1,3-thiazolidin-3-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5,6-dihydro-4H-thieno[3,2-b]pyrrol-4-yl, hexahydro-4H,-thieno[3,2-b]pyrrol-4-yl, 2,3-dihydro-1H-thieno[3,4-b]pyrrol-1-yl, 1,3-benzothiazol-3(2H)-yl, 1,3-benzoxazol-3(2H)-yl, pyrazolo[1,5-al]pyridin-1 (2H)-yl, 3,4-dihydroisoquinolin-2(1H)-yl, 3,4-dihydroquinolin-1(2H)-yl, 1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl, 1,2,4,5-tetrahydra-3H-3-benzazepin-3-yl; for the manufacture of a medicament for the treatment or prevention of CNS disorders including epilepsy.

Abstract translation: 本发明涉及具有式（I）的化合物，其几何异构体，对映体，非对映异构体及其混合物或其药学上可接受的盐，其中Y是O，S或NR8; R1是氢或C1-6烷基; R2是氢; R3是-CONR5R6，-COR7，咪唑基，咪唑并吡啶基，咪唑并哒嗪基或1H-吲哚-1-基; R5，R6相同或不同，独立地选自氢和C1-6烷基; R7是C1-6烷基; R8是CN或C1-6烷基磺酰基; A是选自咪唑烷-1-基，1,3-恶唑烷-3-基，2,5二氢-1H-吡咯-1-基，1,3-噻唑-3（ 2H） - 基，1,3-噻唑烷-3-基，吡咯烷-1-基，哌啶-1-基，氮杂环庚烷-1-基，5,6-二氢-4H-噻吩并[3,2-b]吡咯 -4-基，六氢-4H - 噻吩并[3,2-b]吡咯-4-基，2,3-二氢-1H-噻吩并[3,4-b]吡咯-1-基， 苯并噻唑-3（2H） - 基，1,3-苯并恶唑-3（2H） - 基，吡唑并[1,5-a]吡啶-1（2H） - 基，3,4-二氢异喹啉-2（1H） 3,4-二氢喹啉-1（2H） - 基，1,3,4,5-四氢-2H-苯并吖庚因-2-基，1,2,4,5-四氢-3H-3-苯并吖庚因 -3-基; 用于制备用于治疗或预防包括癫痫在内的CNS疾病的药物。

公开(公告)号：WO2006128693A3

公开(公告)日：2007-04-19

申请号：PCT/EP2006005200

申请日：2006-05-31

Applicant: UCB PHARMA SA ,  KENDA BENOIT ,  QUESNEL YANNICK ,  ATES ALI ,  MICHEL PHILIPPE ,  TURET LAURENT ,  MERCIER JOEL

Inventor： KENDA BENOIT ,  QUESNEL YANNICK ,  ATES ALI ,  MICHEL PHILIPPE ,  TURET LAURENT ,  MERCIER JOEL

IPC: C07D401/06 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/435 ,  C07D403/06 ,  C07D473/00

CPC classification number: C07D513/04 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04

Abstract: The present invention concerns 2-oxo-1 -pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Abstract translation: 本发明涉及2-氧代-1-吡咯烷衍生物，其制备方法，含有它们的药物组合物及其作为药物的用途。

公开(公告)号：BR112012009310A2

公开(公告)日：2016-06-07

申请号：BR112012009310

申请日：2010-10-21

Applicant: UCB PHARMA SA

Inventor： MERCIER JOËL ,  TURET LAURENT ,  QUESNEL YANNICK

IPC: C07D513/04 ,  A61K31/433 ,  A61P25/08

Abstract: composto, e, composição farmacêutica. a presente invenção se refere a derivados de 2-oxo-1-pirrolidino imidazotiadiazol derivadas, processos para prepará-los, composições farmacêuticas que os contenham e seu uso como produtos farmacêuticos.

公开(公告)号：AU2006254336B9

公开(公告)日：2013-02-28

申请号：AU2006254336

申请日：2006-05-31

Applicant: UCB PHARMA SA

Inventor： TURET LAURENT ,  ATES ALI ,  QUESNEL YANNICK ,  MERCIER JOEL ,  MICHEL PHILIPPE ,  KENDA BENOIT

IPC: C07D401/06 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/435 ,  C07D403/06 ,  C07D473/00

Abstract: The present invention concerns 2-oxo-1 -pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

公开(公告)号：BRPI0615830A2

公开(公告)日：2012-12-18

申请号：BRPI0615830

申请日：2006-09-12

Applicant: UCB PHARMA SA

Inventor： ATES CELAL ,  QUESNEL YANNICK ,  SCHULE ARNAUD ,  LURQUIN FRANCOISE

IPC: C07D207/26

Abstract: The present invention relates to optically enriched or substantially optically pure 4-substituted-pyrrolidin-2-ones of formula (III), and their uses for the synthesis of 2-oxo-pyrrolidin-1-yl derivatives.

公开(公告)号：NZ566240A

公开(公告)日：2011-05-27

申请号：NZ56624006

申请日：2006-09-12

Applicant: UCB PHARMA SA

Inventor： ATES CELAL ,  LURQUIN FRANCOISE ,  QUESNEL YANNICK ,  SCHULE ARNAUD

IPC: C07D207/26

Abstract: Disclosed is a substantially optically pure 4-substituted-pyrrolidin-2-one of formula (III), wherein R1 is ethyl, n-propyl, a C1-3 alkyl substituted by at least one halogen or a alkenyl substituted by at least two halogen atoms; and wherein substantially optically pure means that at least 95% of the compound of formula (III) has the stereogenic center indicated by (1*) in a given configuration (R) or (S). Also disclosed is a process to prepare said pyrrolidin-2-one.

公开(公告)号：DE602004019814D1

公开(公告)日：2009-04-16

申请号：DE602004019814

申请日：2004-11-29

Applicant: UCB PHARMA SA

Inventor： KENDA BENOIT ,  MICHEL PHILIPPE ,  QUESNEL YANNICK

IPC: C07D207/26 ,  C07D207/263 ,  C07D207/27 ,  C07D403/06 ,  C07D403/08

Abstract: The present invention relates to imidazole derivatives of the formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

公开(公告)号：ES2530398T3

公开(公告)日：2015-03-02

申请号：ES06791987

申请日：2006-09-12

Applicant: UCB PHARMA SA

Inventor： ATES CÉLAL ,  LURQUIN FRANCOISE ,  QUESNEL YANNICK ,  SCHULE ARNAUD

IPC: C07D207/26

Abstract: Pirrolidin-2-onas 4-sustituidas sustancialmente ópticamente puras de fórmula (III),**Fórmula** en donde R1 es etilo, n-propilo, un alquilo C1-3 sustituido con por lo menos un halógeno o un alquenilo C2-4 sustituido con 1 a 5 átomos de halógeno.

公开(公告)号：CA2620243C

公开(公告)日：2015-01-20

申请号：CA2620243

申请日：2006-09-12

Applicant: UCB PHARMA SA

Inventor： ATES CELAL ,  LURQUIN FRANCOISE ,  QUESNEL YANNICK ,  SCHULE ARNAUD

IPC: C07D207/26

Abstract: The present invention relates to optically enriched or substantially optically pure 4-substituted-pyrrolidin-2-ones of formula (III), and their uses for the synthesis of 2-oxo-pyrrolidin-l-yl derivatives.